SLC6A8 expression was significantly associated with the overall survival (OS) of BRCA, LGG, mesothelioma (MESO), and prostate adenocarcinoma (PRAD), disease free interval (DFI) of BRCA and PRAD, disease specific survival (DSS) of LGG, LUAD, MESO, PRAD, and uveal Melanoma (UVM), progression free interval (PFI) in BRCA, MESO, and PRAD (Figures 2A–D). The gene discussed is SLC6A8; the disease is prostate adenocarcinoma.